AGP Picks
View all

Aruba Health Monitor
Provided by AGP

Aruba Health Monitor: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Aruba Health Monitor.

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

November 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30

Press releases published on November 12, 2026

Altimmune Announces Third Quarter 2026 Financial Results and Business Update
Nov. 12, 2026

Altimmune Announces Third Quarter 2026 Financial Results and Business Update

Indeterminate GlobeNewswire
Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
Nov. 12, 2026

Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16

Indeterminate GlobeNewswire
Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
Nov. 12, 2026

Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer

Indeterminate GlobeNewswire
Avicanna Reports Positive Adjusted EBITDA for Q3 2026 and Provides Corporate Update
Nov. 12, 2026

Avicanna Reports Positive Adjusted EBITDA for Q3 2026 and Provides Corporate Update

Indeterminate GlobeNewswire
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov. 12, 2026

Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Indeterminate GlobeNewswire
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
Nov. 12, 2026

Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients

Indeterminate GlobeNewswire
Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise
Nov. 12, 2026

Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise

Indeterminate GlobeNewswire
MediPharm Labs Reports Q3 2026 Results with Second Consecutive Quarter of Positive Net Income and 18% Sequential Revenue Growth
Nov. 12, 2026

MediPharm Labs Reports Q3 2026 Results with Second Consecutive Quarter of Positive Net Income and 18% Sequential Revenue Growth

Indeterminate GlobeNewswire
Dyadic’s C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations
Nov. 12, 2026

Dyadic’s C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations

Indeterminate GlobeNewswire
Ascendis Pharma Reports Third Quarter 2026 Financial Results
Nov. 12, 2026

Ascendis Pharma Reports Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire
Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov. 12, 2026

Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update

Indeterminate GlobeNewswire
Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology
Nov. 12, 2026

Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology

Indeterminate GlobeNewswire
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
Nov. 12, 2026

NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury

Indeterminate GlobeNewswire
Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Nov. 12, 2026

Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

Indeterminate GlobeNewswire
Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference
Nov. 12, 2026

Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference

Indeterminate GlobeNewswire
Maple Report: More than half of Canadian patients and families report being left without adequate updates while waiting for care
Nov. 12, 2026

Maple Report: More than half of Canadian patients and families report being left without adequate updates while waiting for care

Indeterminate GlobeNewswire
ProQR Announces Third Quarter 2026 Operating and Financial Results
Nov. 12, 2026

ProQR Announces Third Quarter 2026 Operating and Financial Results

Indeterminate GlobeNewswire
AAVantgarde to present progress toward the first treatment for Usher syndrome type 1B at EYENOVATE and FLORetina 2026
Nov. 12, 2026

AAVantgarde to present progress toward the first treatment for Usher syndrome type 1B at EYENOVATE and FLORetina 2026

Indeterminate GlobeNewswire
TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov. 12, 2026

TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire
MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov. 12, 2026

MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Aruba Health Monitor

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.